You are here

Avastin Biosimilar Submitted for FDA Review

Phase 3 study finds no meaningful differences between ABP 215 and bevacizumab

A biologics license application (BLA) has been filed with the FDA for ABP 215 (Amgen/Allergan), a biosimilar candidate to bevacizumab (Avastin, Genentech). The product’s developers believe that this is the first bevacizumab biosimilar application to be submitted to the agency.

Bevacizumab is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF with its receptors, VEGF-1 and VEGF-2, thereby inhibiting the angiogenesis necessary for the maintenance and growth of solid tumors.

The BLA submission included analytical, pharmacokinetic, and clinical data, as well as pharmacology and toxicology data. A phase 3 comparative efficacy, safety, and immunogenicity study was conducted in adults with nonsquamous non–small-cell lung cancer (NSCLC). The study confirmed that there were no clinically meaningful differences between ABP 215 and bevacizumab in terms of efficacy, safety, and immunogenicity.

Bevacizumab is approved in the U.S for the treatment of patients with unresectable, locally advanced, recurrent or metastatic nonsquamous NSCLC as well as for the treatment of patients with metastatic carcinoma of the colon or rectum; metastatic renal-cell carcinoma; and other region-specific indications.

Source: Amgen; November 15, 2016.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions